Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

ed at the end of 2006.

Our process development expenses for the first quarter of 2008 were $35,766 compared to $89,776 for the first quarter of 2007. In the first quarter of 2008, our process development focus continues to be on the scale up to 100-litre production runs. In the first quarter of 2007, our process development focus was on our earlier 40-litre scale up studies.

We still expect that our M&P expenses for 2008 will increase compared to 2007. We have initiated our 40-litre production runs which will continue throughout 2008. As well, we still expect to finalize our 100-litre scale up studies and continue the examination of a lyophilization process for REOLYSIN(R) in 2008. Once our 100-litre process development studies are complete, we expect to transfer our 100-litre manufacturing process to our cGMP manufacturers.

Clinical Trial Program

2008 2007

$ $

-------------------------------------------------------------------------

Direct clinical trial expenses 994,646 683,107

Other clinical trial expenses 48,145 38,510

-------------------------------------------------------------------------

Clinical trial expenses 1,042,791 721,617

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the first quarter of 2008, our direct clinical trial expenses increased to $994,646 compared to $683,107 for the first quarter of 2007. In the first quarter of 2008, we incurred direct patient costs in our six enrolling clinical trials compared to only three actively enrolling clinical trials in the first quarter of 2007.

We still expect our clinical trial expenses to increase i
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Genomics and Proteomics Analytical Instruments Market ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the ... is the study of the structure and functions of ... and bioinformatics tools and technology. Genomics involves the mapping ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
(Date:7/24/2014)... 24, 2014 Draper University, a ... proud to announce that for 6 weeks this ... will converge on the Draper University campus in ... experiential program focused on entrepreneurship, building real-world skills, ... currently running its sixth cohort, continues to refresh ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3
... Laureate To Manufacture Tolera,s Monoclonal Antibody Product ... Laureate Pharma, Inc., a,full-service biopharmaceutical development ... has entered into a cGMP contract manufacturing,agreement ... that,develops and offers targeted therapies and safer ...
... will feature Ziplex automated gene-expression system at the ... ... Xceed Molecular, a pioneer in,the development of cost-effective, easy-to-use ... Dr. James L. Wittliff, a professor in the Department of,Biochemistry ...
... ... Gardner, Mass. (PRWEB) October 28, 2008 -- New England Peptide, ... formed scientific advisory board., , ,Vincent Bille, Tomi Sawyer and Ved ... thought leaders in peptide chemistry. The group will assist in formulating ...
Cached Biology Technology:Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc. 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 3New England Peptide Forms Scientific Advisory Board 2New England Peptide Forms Scientific Advisory Board 3New England Peptide Forms Scientific Advisory Board 4
(Date:7/25/2014)... tractography (DTT), which is derived from diffusion tensor ... motor tracts, such as the corticospinal tract, the ... The corticospinal tract is known to be a ... human brain. Several studies have reported on injury ... addition, some studies have demonstrated recovery of a ...
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2
... discovered that a poorly understood class of RNA produced in ... the outcome of the infection. Their findings are reported ... Society for Microbiology. RNA (ribonucleic acid) contains information transcribed ... known of these RNAs translate sections of DNA code into ...
... St. Louis, MO, October 26, 2010 Periodontitis, a ... teeth, leads to accumulation of bacteria and potential bone ... bacterial infection, more recent strategies target the inflammatory response. ... Journal of the American Dietetic Association , researchers ...
... Food and Agriculture (NIFA) awarded a $1.5 million grant ... for increasing environmental, social, and economic sustainability in ornamental ... the U of I Department of Crop Sciences said ... crop production systems is waste generation due to the ...
Cached Biology News:New class of biomolecules triggered in response to respiratory virus infection 2New class of biomolecules triggered in response to respiratory virus infection 3New class of biomolecules triggered in response to respiratory virus infection 4Consuming polyunsaturated fatty acids may lower the incidence of gum disease 2U of I receives $1.5 million to further sustainability in ornamental crop production 2U of I receives $1.5 million to further sustainability in ornamental crop production 3
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
... and conveniently controls the temperature at your lab ... levels up to 99 C*, with the "plus" ... as 5 C. The thermoblocks for 0.2 ml**, ... microplates enable a high degree of flexibility for ...
...
... powerful tool for sample purification in microbiological ... or protein purification as well as cell ... on the Genesis Series of instruments using ... with the RoMa arm and Tecans powerful ...
Biology Products: